First Choice Neurology

Medicare

Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients

By Jeffrey Gelblum, MD As a practicing neurologist with over 25 years of experience treating Alzheimer’s disease, I strongly oppose the proposed intention of Centers for Medicare & Medicaid Services (CMS) to restrict coverage of anti-amyloid antibody therapy to only those patients who must participate in an approved hospital-based clinical trial (Coverage with Evidence Development, …

Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients Read More »

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients

Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as aducanumab, the $56,000-a-year drug helps patients. There is also uncertainty about reimbursement from Medicare. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) …

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders

Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the specific daily impact of dementia on my patients and allows me to implement a meaningful treatment plan. This plan can include medication as well as …

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders Read More »

Translate »